Category Archives: Parkinson’s Treatment

This article was originally published here Pharmaceutics. 2020 Nov 20;12(11):E1120. doi: 10.3390/pharmaceutics12111120. Continue reading →

Clene Chief Executive Officer Rob Etherington. Photo courtesy of Clene Continue reading →

The agreement looks to harness Artificial Intelligence (AI) in their hunt for these biomarkers, employing Ardigens microbiome platform with The BioCollectives stool sample data collected from PD patients. Parkinsons is an incredibly complex systemic disease and clues to untangling that complexity are increasingly revealed in the microbiome, reveals Martha Carlin, CEO of The BioCollective. We believe that this partnership will help progress our collective understanding of the microbiomes role in human health, and that combining our microbiome expertise with exciting AI tools like those developed by Ardigen will translate exponentially to combat diseases like Parkinsons, and beyond. Continue reading →

HAIFA, Israel and MIAMI, Nov. 24, 2020 /PRNewswire/ --INSIGHTEC, a global healthcare company focused on the therapeutic power of acoustic energy, today announced that the National Health Service (NHS) England has approved funding for MR-guided Focused Ultrasound for the treatment of medication-refractory Essential Tremor patients from April 2021.The NHS England is the publicly funded healthcare system for England Continue reading →

UCB The report further sheds light on the various strategic business initiatives undertaken by the key market contenders to fortify their foothold in this business sector. These strategies majorly include mergers & acquisitions, partnerships & collaborations, joint ventures, government and corporate deals, brand promotions, new product launches, and numerous others. In the later part of the report, the major components of the Parkinsons Disease Treatment industry, such as product type, application gamut, end-use industries, and the solutions and services offered by the leading manufacturers, have been analyzed Continue reading →

DataIntelo offers a detailed report on Global Parkinsons Disease Treatment Market. Continue reading →

Details Category: Proteins and Peptides Published on Monday, 02 November 2020 14:51 Hits: 307 Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death Concurrent Phase 2 Clinical Trial is Evaluating NLY01 for Parkinsons Disease GAITHERSBURG, MD, USA I November 02, 2020 INeuraly, Inc., a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimers disease. NLY01 is also being evaluated in patients with Parkinsons disease in a Phase 2 trial initiated in February 2020. Continue reading →

Parkinson's disease is a common neurodegenerative disorder affecting middle-aged and elderly people. It is a disease characterised by a deficiency of dopamine in areas of the midbrain causing a variety of movement problems such as akinesia (the loss of ability to move your muscles voluntarily), rigidity, and tremor. The eyes may also be affected with this condition and if suffering from any of these eleven vision symptoms, it could mean you may be at risk. Continue reading →

November 03, 2020 07:00 ET | Source: Aquestive Therapeutics, Inc. WARREN, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc Continue reading →

The move follows the merger it announced late last month with the NASDAQ listed, Longevity, a special purpose acquisition company (SPAC). 4D Pharma will become dual-listed and ordinary shares will continue to be traded on AIM Continue reading →